Several established drugs for treating major mental illnesses have been found to possess new therapeutic uses. Among them, for example, are the inhibitors for monoamine oxidase (MAO inhibitors) which can be used to alleviate the symptoms associated with Parkinson's disease in addition to their traditional therapeutic actions for treating mental disorders. One innovative area has investigated the neuroprotective effects of MAO inhibitors through the disruption of the movement of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) into the cell nucleus because GAPDH has recently been confirmed to be a cell death mediator by translocating into the nucleus and triggering cell death pathways.
This Research Topic will target many other mental health medications and will not only display the newly discovered positive applications of proven psychiatric drugs from both basic and clinic aspects, but also update their negative components as well as possible challenges. Collectively, this study will bring together contributions from various leading experts in the field of psychiatric pharmacology.
Several established drugs for treating major mental illnesses have been found to possess new therapeutic uses. Among them, for example, are the inhibitors for monoamine oxidase (MAO inhibitors) which can be used to alleviate the symptoms associated with Parkinson's disease in addition to their traditional therapeutic actions for treating mental disorders. One innovative area has investigated the neuroprotective effects of MAO inhibitors through the disruption of the movement of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) into the cell nucleus because GAPDH has recently been confirmed to be a cell death mediator by translocating into the nucleus and triggering cell death pathways.
This Research Topic will target many other mental health medications and will not only display the newly discovered positive applications of proven psychiatric drugs from both basic and clinic aspects, but also update their negative components as well as possible challenges. Collectively, this study will bring together contributions from various leading experts in the field of psychiatric pharmacology.
